Scarica l'app Stockscreener
76.99
1.00%
-0.78
Dopo l'orario di chiusura:
77.54
0.55
+0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$77.77
Aprire:
$76.74
Volume 24 ore:
1.07M
Relative Volume:
0.62
Capitalizzazione di mercato:
$13.94B
Reddito:
$342.96M
Utile/perdita netta:
$-864.29M
Rapporto P/E:
-13.87
EPS:
-5.55
Flusso di cassa netto:
$-636.03M
1 W Prestazione:
+4.46%
1M Prestazione:
-5.37%
6M Prestazione:
+5.65%
1 anno Prestazione:
+194.53%
Intervallo 1D:
$75.81
$77.76
Intervallo di 1 settimana:
$73.01
$78.18
Portata 52W:
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
76.99 | 13.94B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.23 | 131.54B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
664.96 | 72.70B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
611.18 | 37.14B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.30 | 31.63B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
261.38 | 28.10B | 3.32B | -860.46M | -1.04B | -8.32 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Is Insmed Incorporated (INSM) a Best Biotech Stock According to Billionaires? - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Truist maintains Buy on Insmed stock, sees PAH data as positive - Investing.com Australia
US Bancorp DE Boosts Holdings in Insmed Incorporated (NASDAQ:INSM) - Defense World
Truist maintains Buy on Insmed stock, sees PAH data as positive By Investing.com - Investing.com South Africa
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch By Investing.com - Investing.com South Africa
Insider Sell: Roger Adsett Sells 42,975 Shares of Insmed Inc (IN - GuruFocus.com
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch - Investing.com
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Smartleaf Asset Management LLC - Defense World
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -March 10, 2025 at 08:01 am EDT - Marketscreener.com
Insmed Expands Team with Stock Options Grant to 18 New Hires - StockTitan
UBS Group Raises Insmed (NASDAQ:INSM) Price Target to $110.00 - Defense World
Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating - TipRanks
UBS raises Insmed stock price target to $110 By Investing.com - Investing.com UK
Insmed CEO Lewis sells $1.99 million in stock By Investing.com - Investing.com Australia
Insmed CEO Lewis sells $1.99 million in stock - Investing.com India
Amalgamated Bank Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Sanctuary Advisors LLC Acquires 464 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
RBC Capital starts Insmed at Outperform on brensocatib launch momentum - MSN
Guggenheim Reaffirms Buy Rating for Insmed (NASDAQ:INSM) - MarketBeat
Investor Network: Insmed Incorporated to Host Earnings Call - ACCESS Newswire
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - Pink Sheet
Truist Financial Corp Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed (NASDAQ:INSM) Now Covered by Royal Bank of Canada - MarketBeat
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates - MSN
RBC Capital Initiates Coverage of Insmed (LSE:0JAV) with Outperform Recommendation - Nasdaq
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga India
RBC Capital sets $100 price target on Insmed stock with Outperform rating - Investing.com Canada
RBC Capital Initiates Coverage of Insmed (INSM) with Outperform Recommendation - MSN
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says -February 25, 2025 at 12:09 pm EST - Marketscreener.com
FDA sets PDUFA date for Insmed's bronchiectasis drug By Investing.com - Investing.com Australia
FDA sets PDUFA date for Insmed’s bronchiectasis drug By Investing.com - Investing.com Nigeria
Insmed’s Brensocatib Receives FDA Priority Review - TipRanks
International Markets and Insmed (INSM): A Deep Dive for Investors - Yahoo Finance
FDA sets PDUFA date for Insmed's bronchiectasis drug - Investing.com India
FDA sets PDUFA date for Insmed’s bronchiectasis drug - Investing.com
Could This Novel Drug Transform Bronchiectasis Treatment? FDA Signals Confidence in Brensocatib - StockTitan
Insider Sell: Sara Bonstein Sells 18,322 Shares of Insmed Inc (I - GuruFocus.com
Truist Financial Increases Insmed (NASDAQ:INSM) Price Target to $108.00 - Defense World
UBS raises Insmed stock target to $105, maintains buy rating By Investing.com - Investing.com Nigeria
Insmed’s Earnings Call Highlights Record Growth and Strategic Moves - TipRanks
Insmed (NASDAQ:INSM) Shares Gap Down on Disappointing Earnings - MarketBeat
UBS Adjusts Insmed Price Target to $105 From $84, Maintains Buy Rating -February 21, 2025 at 10:46 am EST - Marketscreener.com
Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Reven - GuruFocus.com
UBS raises Insmed stock target to $105, maintains buy rating - Investing.com India
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Mar 03 '25 |
Option Exercise |
22.76 |
18,750 |
426,750 |
352,936 |
| Lewis William | Chair and CEO |
Mar 03 '25 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Mar 03 '25 |
Sale |
77.79 |
18,750 |
1,458,519 |
334,186 |
| Lewis William | Chair and CEO |
Mar 03 '25 |
Sale |
77.79 |
6,830 |
531,278 |
233,924 |
2.73%
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):